… We performed a retrospective, multicenter, cohort analysis of 44 CD pediatric patients
with moderate–severe CD activity who had been treated with Ifx and were switched to Ada …

… (5) Study design: randomized controlled trials (RCTs) and retrospective or prospective
cohort studies assessing predefined outcomes; case–control studies and conference abstract …

… However, pediatric data are limited. This study aimed to assess the … and safety of adalimumab
biosimilar (ADL-BioS) in pediatric IBD patients. Methods: All consecutive pediatric IBD …

… In a 2018 retrospective study in Spain, ADL treatment results … personalized anti TNF therapy
in CD study (PANTS) of children … However, this study was conducted retrospectively, and the …

… anti-TNF therapy 1, 2, and 3 years after initiation. Results: In total, 2,464 papers were screened,
94 were selected for full text review… two of these to be retrospective cohort studies [19,20]. …

… ” to anti-TNF therapy (including … pediatric studies: Although 1 previous retrospective study
demonstrated a higher remission rate with ADL combination therapy, 18 another retrospective …

… because 95% of the patients in the RESEAT registry had previously received infliximab, and
… retrospective study of 62 pediatric patients treated with ADA as first-line anti-TNFα therapy …

… the therapeutic approach and disease course of pediatric inflammatory bowel disease (IBD).
In particular, drugs such as infliximab (IFX) and adalimumab … a retrospective analysis of data …

… One of the first studies to demonstrate the efficacy of adalimumab in pediatric CD patients …
was the Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) …

… In the group that received infliximab, 9 had previously failed on adalimumab therapy due
to … The main finding of our retrospective cohort study of patients with ileocolonic CD treated …